肝纤维化的可逆性

Reversibility of Liver Fibrosis
Teerha Piratvisuth
Prince of Songkla University， Thailand

On the third day of APSAL， Professor Teerha Piratvisuth presented a lecture on reversibility of Liver Fibrosis. He said evidence of fibrotic or cirrhotic regression in human had been reported in chronic liver diseases of different etiologies including viral hepatitis. Improvement in liver fibrosis after longtern anti HBV treatment has been shown in many studies which have paired liver biopsy. Serpaggi etal reported disappearance of cirrhosis， defined as a decrease of 2 or greater in METAVIR fibrosis score in 14 (12.4%) of the 113 cirrhotic patients who received specific therapy. Poynard also confirmed the reversal of cirrhosis in 75 (49%) of 153 chronic hepatitis C patients who were treated with Peginterferon with or without ribavirin.

Moreover，he mentioned that non-invasive methods for evaluation of liver fibrosis， such as fibro-test， fibroscan etc， might be useful for monitoring fibrosis regression. However， study to validate the use of these non-invasive methods is essential before applying.

在APASL大会第三天，Teerha Piratvisuth教授针对肝纤维化的可逆性做了大会报告。他指出已有证据表明人肝纤维化或肝硬化存在可逆性。HBV感染者延长抗病毒治疗时间可改善肝纤维化程度。有报导经聚乙二醇化干扰素±利巴韦林治疗慢性丙型肝炎患者，其中49%肝硬化得到改善。此外，他还谈到了评价肝纤维化程度的无创检测方法的应用前景，但目前这些无创方法实际应用前尚需进一步评价。